Online inquiry

IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7829MR)

This product GTTS-WQ7829MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GLP1R gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002062.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2740
UniProt ID P43220
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ7829MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14213MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG4934
GTTS-WQ4533MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ9788MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ13996MR IVTScrip™ mRNA-Anti-GP, REGN-3470-3471-3479(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-3470-3471-3479
GTTS-WQ3740MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ13154MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-04383119
GTTS-WQ15828MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ961MR IVTScrip™ mRNA-Anti-CD40, ABBV-323(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-323
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW